Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127191561 | 12719156 | 1 | I | 2016 | 20160728 | 20160907 | 20160907 | PER | US-JNJFOC-20160725881 | JANSSEN | 0.00 | A | F | Y | 52.16000 | KG | 20160907 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127191561 | 12719156 | 1 | PS | FENTANYL. | FENTANYL | 1 | Transdermal | STARTED TWO YEARS AGO | N | U | UNKNOWN | 19813 | UNSPECIFIED | ||||||
| 127191561 | 12719156 | 2 | SS | DURAGESIC | FENTANYL | 1 | Transdermal | DURAGESIC STARTED YEAR AND A HALF AGO | N | 150982421 | 19813 | UNSPECIFIED | |||||||
| 127191561 | 12719156 | 3 | SS | TECFIDERA | DIMETHYL FUMARATE | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127191561 | 12719156 | 1 | Pain |
| 127191561 | 12719156 | 2 | Pain |
| 127191561 | 12719156 | 3 | Multiple sclerosis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127191561 | 12719156 | Drug dose omission | |
| 127191561 | 12719156 | Flushing | |
| 127191561 | 12719156 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127191561 | 12719156 | 3 | 2016 | 0 |